



To mitigate the problem of low antiretroviral therapy (ART) 
uptake,	 the	 2013	World	 Health	 Organization	 (WHO),	
consolidated ART guidelines, highlighted the need for 
decentralization of ART care as an acceptable part of a 
global effort to scale up ART uptake.[1] This was based on 
studies showing that; scale-up using this model resulted 
in a significant decline in deaths from AIDS-related 
causes.[2] In low- and-middle-income countries such as 
Nigeria,	decentralization	of	HIV	care	was	projected	to	help	
avert millions of deaths and prevent an additional three and 
a half million new infections between 2012 and 2025.[3] 
Earlier,	 decentralization	models	 had	 facilitated	 significant	
improvement in retention in care (RIC) (since drugs were better 
accessible), better viral suppression, and by extension drop in 
rates of new transmissions and better outcomes.[4-7] The loss 
to follow-up at our facility was rising.
To	 ensure	 retention	 of	 HIV‑positive	 patients	 in	 care,	
(RIC), at the facility, certain interventional models were 
piloted, adopted and deployed as differentiated models 
of care (DMCs), namely; community Anti-retroviral 
group	(community	antiretroviral	group	[CAG]),	task‑shifting,	
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fast track, community pharmacy services, and multi-months 
scripting.
The	CAG	model,	 in	 particular,	 supported	 by	 the	 facility	
partner,	the	Institute	of	Human	Virology,	Nigeria	(IHVN),	was	
deployed in January 2017. The aims of the intervention were; 
to	ensure	or	facilitate	access	to	regular	drug	refills,	to	ensure	
RIC, to reduce clinic workload while ensuring good quality 
of life as well as top quality of care.
Studies elsewhere have reported successes achieved with the 
CAG	model.[4,5,7] Similar studies from Nigeria that assessed the 
impacts of this model are sparse. Thus 2 years on, it is time 
to assess some impacts this intervention may have had on the 
pilot cohort and on the system. This study is designed to assess 
the	impacts	of	the	CAG	model	on	the	patients,	(individual	or	
group), and the hospital facility.
Methods
Study setting
The study was conducted at a tertiary facility in Abuja, the 
Federal Capital Territory (FCT), after ethical clearance, which 
was obtained from the Ethical and Research Committee of 
the	Asokoro	District	Hospital,	Abuja	(Approval	code	FCTA/
HHSS/ADH/EC/0051/18).	The	FCT	is	located	in	the	center	of	
Nigeria, with a current population of approximately 3.3 million 
inhabitants.[8] Our facility is a 154-bed tertiary health-care 
outfit	and	provides	services	in	all	major	medical	specialties.	
FCT	has	an	adult	HIV	prevalence	estimated	at	1.5%,[9] and its 
center, Abuja, tops the list of expensive cities in Nigeria.[10] 
It is surrounded by suburbs that house most of the people 
working in Abuja. Those needing health-related attention, 
travel	long	distances,	and	through	strenuous	traffic	hold‑ups	
with attendant risks, to access hospital services. Our facility 
currently	 cares	 for	 about	five	 thousand	 active	 adult	 people	
living	with	HIV	(PLHIV).
Patient selection‑eligibility criteria
This study was a follow-up on a cohort of patients who piloted 
the	CAG	interventional	model	in	the	hospital.	For	that	cohort,	
eligibility criteria were; Young adults who were clinically 
stable,	virally	suppressed	(defined	by	viral	load	of	<20	copies/
ml)	 on	first‑line	 regimen,	 no	 opportunistic	 infection	 (OI),	
not pregnant. Clients who failed to meet these criteria were 
excluded.
The CAG model; description and standard operating 
procedure.
Background information
As displayed in Table 1, there were fourteen groups in this pilot 
intervention. Each group had six members. The members of 
each group lived in the same catchment area, for proximity 
reasons. This arrangement was agreed to by each member 
before placement was made.




enrolment were done by the clinic manager. This is usually 
during the routine health education done before the day’s clinic 
commences. The support-group also acted as another platform 
for	 such	awareness.	Copies	of	 the	SOP	were	distributed	 to	
clients.	Those	who	opted	for	CAG	were	screened	using	the	
eligibility criteria before they were grouped accordingly.
After enrolment, the knowledge capacity of each group 
member was developed during the two meetings held with all 
groups, to ensure synergy between individuals within each 
group. Clients opted for the meetings willingly; no incentives, 
transportation,	or	accommodation	were	provided.	The	SOP	was	
explained	 in	Pidgin‑English,	 good	English,	Hausa,	Yoruba,	
and Ibo, by the Nursing team and support counselors from 
the	IHVN.	Self‑designed	client,	 [Table 2a], and health-care 
providers, [Table 2b] questionnaires were completed during 
the second meeting after enrolment, at the commencement of 
CAG.	A	lead	person	was	chosen	for	each	group	by	the	group	
members themselves. This lead coordinated the group activities 
and functioned as a spokesperson for the group.
At the facility
Figure 2	 is	 the	flow	chart.	On	bi‑monthly	 basis,	 on	behalf	
of the group, a member visited the hospital, reported at the 
CAG‑desk	manned	 by	 the	CAG	anchorperson	 (who	 is	 an	
expert-client on hospital payroll). The anchor enabled the 
process by withdrawing/posting the ART cards of all members 
of that particular group to the Doctor. That member attended the 
health talk [Figure 3a], got nursing observation which included; 
anthropometric measures and blood pressure checks, received 
medical consultation with the Doctor, attended adherence 
counseling session [Figure 3b], reported on the adherence 
status of fellow group members, received laboratory attention 




monitored and evaluated the quality of care and coordinated 
the	implementation	of	the	CAG	model.
In the community
Back	 in	 the	community,	 the	member	who	visited	 the	clinic	
that month distributed the drugs to the other group members 
Figure	3d.	Group	members	met	 regularly	 to	do	pill	counts,	
counsel each other on adherence issues/daily problems 
encountered and support each other psychologically.
Follow‑up/support
The	 clinic	manager	 and	 the	CAG	desk‑officer	 participated	
in the community meetings on invitation by the group. Any 
member reporting symptoms that suggested illness, adverse 
drug effects, or weight loss was referred back to the facility 
immediately for prioritized assessment by a physician. All 
members saw a physician at least twice a year for a general 
check-up.
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Data collection
Data, (qualitative and quantitative) was pooled from the 
CAG	 register,	 into	 Excel	 Spread	 sheet	 then	 exported	 to	
SPSS	 21	 (IBM,	USA)	 for	 the	 analysis.	 Qualitative	 data	
were also obtained from the self-designed questionnaires 
for clients [Table 2a] and health-care givers [Table 2b]. 
The	CAG	register	contains	the	enrolment	data	and	through	
follow-ups of all the persons on this pilot of DMC. Such data 
include name, age, sex, enrolment number, the community 
where they live, viral load, duration on ARV prior to 
enrolment	in	CAG,	the	ART	regimen,	height,	weight,	body	
mass	index	(BMI),	packed	cell	volume	(PCV),	CD4	count,	
blood pressure, and adherence rates. The questionnaires 
were completed during the second meeting after enrolment, 
at	the	commencement	of	CAG.	Caregivers	were;	doctors,	
nurses,	 laboratory	 scientists,	 records	 officers,	 adherence	
counselors, and pharmacists. Data obtained at entry were 
then compared with similar data 2 years after, to examine 
the changes that may have occurred.





standard deviations (SDs) were determined. A paired sample 
test was used to compare the means of variables before and 
after	the	CAG	intervention.	Chi‑square	test	was	used	to	check	
for	statistical	significance,	and	a P <	0.05	set	as	a	significant	
level. There were eight locations with 84 clients, 62 females 
and 22 males, [Table 1] placed in fourteen groups, each 
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with six clients. The locations and number of groups (ng), 
in each location, are shown in Table 1. The mean age was 
39.38 ± 9.68 years. The distance between each location and 
the facility are shown in Table 1 and ranged from 5.4 km to 
17.3 km. The average distance was 12.56 km ± 3.78; with a 
mean return transport cost per clinic visit, per visiting client, 
of	996.4	±	183.3	Naira.	Per	clinic,	per	group,	one	member	
visits, thus saving about 4980 Naira for the group. This 
totals about 69,720 Naira, at least, for all 14 groups. Thus in 
1 year, (bi-monthly visits), at least 418,320 Naira was saved. 
Over	the	2	years	period	of	CAG,	for	this	pilot	group	of	just	
eighty-four clients, at least 836,640 Naira was saved. This 
is a reasonable sum of money that must have gone a long 
way in improving the lives of the clients. Table 3 shows the 
means	 and	SDs	of	variables	prior	 to	 engagement	 in	CAG	
and	then	2	years	on	in	CAG.	The	following	variables	were	
documented;	 height	 (H),	weight	 (WT),	BMI,	 systolic	 and	
diastolic	 blood	 pressures,	 PCVs,	 entry	CD4	 counts,	 and	
entry viral loads.
dIscussIon
This	 appears	 to	 be	 the	first	 study	 to	 report	 the	 impacts	 of	
decentralization	in	HIV‑care	in	Nigeria	beyond	the	program.	
Bearing	 the	 second‑largest	 burden	 of	 HIV	 infection	 in	
Africa, Nigeria was observed to have only one-third of 
her	 HIV‑positive	 patients	 having	 acceptable access to 
ART.[12]	Hence,	the	adoption	of	some	strategies	such	as	the	
hub‑and‑spoke	 (HSK),	approach	 in	an	attempt	 to	meet	her	
treatment targets.[6]	Even	though	the	HSK	approach	(which	
involved scaling care to lower levels), helped in decongesting 
crowded clinics, outcomes were not particularly good.[6,13] This 
was thought to be due to the premature enrolment of patients, 
independently by the peripheral facility, irrespective of clinical 
status.[6]	Being	 a	 key	 strategy	 for	 treatment	 expansion,[6,14] 
decentralization	needed	a	review	of	its	approach.	The	CAG,	
a drug delivery model that leverages on lessons learned from 
Table 1: Distances between catchment areas and the 
hospital facility
Location Number of Clients Distance 
(km)Total (84) *M (22) †F (62)
Kobi 6 0 6 10.7
Nyanya- 2 groups 12 3 9 17.3
Kurudu 6 1 5 08.2
Masaka- 4 groups 24 9 15 15.8
Maraba- 3 groups 18 7 11 15.8
Asokoro Extension 6 0 6 11.7
Army	Barracks	Jikwoyi 6 1 5 08.2
Jikwoyi‑Non	Barrack 6 1 5 10.4
*Males, †Females
Table 2: (a) Questionnaire for clients. (b) Questionnaire for caregivers
Questions Yes No Not sure
Do	you	think	this	intervention	model	has	helped	to	reduce	Patients	cost	of	transportation	to	and	
fro	clinic?
(100%) 0 (0%) 0 (0%)
Do	you	think	this	intervention	model	has	helped	you	gain	valuable	time?	 84 (100%) 0 (0%) 0 (0%)
Do you think this intervention model may have improved your income since they had more 
time	for	their	private	businesses	and	concerns?
84 (100%) 0(0%) 0(0%)
Do	you	think	this	model	may	have	helped	to	improve	Your	Wellbeing	and	mutual	peer	support?	 81 (96.4%) 0(0%) 3(3.6%)
As	a	Client,	from	your	observation,	has	this	intervention	reduced	your	clinic	waiting	time? 84 (100%) 0(0%) 0(0%)
‡ERIC §DRIC No influence
How	do	you	think	this	intervention	may	have	influenced	retention	in	care? 80(95.2%) 2(2.4%) 2(2.4%)
GOOD POOR No Influence
How	do	you	think	this	intervention	may	have	affected	Quality	of	care? 81(96.4%) 1(1.2%) 2(2.4%)
Any	Mutual	exchange	of	psychosocial	support? 84(100%) 0(0%) 0(0%)
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community-based management of chronic diseases,[14,15] 
was then a choice model for Nigeria. It borrowed a leaf 
from a Malawi pilot,[4] where chosen stable patients were 
decentralized.	Hence,	the	inclusion	criteria	motioned	above.	
The	CAG	model	was	 piloted	 in	 our	 facility,	 from	 January	
2017	aimed	at	facilitating	access	to	regular	drug	refills,	RIC,	
reduction in clinic workload while ensuring top quality of 
care,	and	more.	The	benefits	of	CAG	and	its	impacts	may	be	
visualized	in	two	folds;	(A)	on	the	patients	and	group	(B)	on	
the hospital facility and system.
Impacts on the patients and group
Virologic and immunologic impacts
Success	 in	HIV‑treatment	 is	 indicated	 by	 the	 sufficiently	
reconstituted immune system to levels where opportunistic 
infections (OIs), become less common and may not 
threaten patient’s survival and quality of life. Achieving and 
maintaining a suppressed viral load, and an adequate level 
of CD4 counts, are vital as many OIs are prevented at higher 
CD4 counts.[16,17] Viral load test remains the gold standard 
for assessing ART response and early detection of treatment 
failure.[17,18] Thus, the ability to maximally suppress viral loads 
to undetectable levels is a key outcome in ART programs.[17,18] 
Variations in the rates of virologic response to treatment and 
care have been reported from settings similar to ours, with 
the majority reporting similar margins of suppression as ours.
[16-19] Although our patients were enrolled with a mean baseline 
viral load that was suppressed, mean/SD of 85.1 ± 182.39, as 
shown in Table 3, their viral load remained suppressed, 2 years 
after,	with	 a	 further	 and	 significant	 reduction,	 (mean/SD,	
31.10 ± 46.648). A similar pattern was observed in the CD4 
values, representing a sustained and impressive immunologic 
response to ART. Similar margins of immunologic response 
to ART, as depicted by CD4, have been reported by previous 
studies from Africa,[6,20-22] with even slightly higher increases 
seen	in	our	study.	Since	the	CAG	model	involves	scale‑out	
to the communities, with a potentially higher burden of OIs, 
the use of prophylactic agents, particularly cotrimoxazole, 




Successful population-level ART adherence will be necessary to 
realize	both	the	clinical	and	prevention	benefits	of	antiretroviral	
scale-up.[23] For chronic disease treatment programs such as 
with	HIV	 to	 succeed,	 long‑term	drug	 adherence	 has	 to	 be	
ensured.	Poor	or	suboptimal	adherence	has	been	reported	to	
be largely responsible for treatment failure in Africa.[6] Our 
study showed a sustained increase in adherence from 87.55% 
at entry, to 100% 2 years after, P < 0.05, Table 2. This was 
made possible by the sustained and assured drug availability, 
corroborating experience from previous studies.[24-26]
Socioeconomic benefits
The	patients	 saved	 time	 and	money.	Before	CAG,	patients	
Table 3: Comparison of means before and after CAG







Weight(kg) 65.94+11.012 70.69+11.465 4.750+5.594 5.964 L 
3.536 U
7.782 83 <0.001
**BMI	(kg/m2) 24.77+3.879 26.79+4.282 2.012+2.402 2.533 L 
1.491 U
7.676 83 <0.001
PCV	(%) 31.19+5.014 35.64+5.131 4.452+3.345 5.178 L 
3.726 U
12.199 83 <0.001
CD4 (cells/mm3) 394.36+193.094 563.87+220.137 169.512+186.017 209.880 L 
129.144 U
8.352 83 <0.001
††VL (copies/ml) 85.06 +182.329 31.10 +46.648 -53.964 +174.453 -16.10L 
-91.823U
- 62.835 83 <0.001
SBP	(mmHg) 124.51+20.984 111.15+18.935 -13.357+15.624 -9.967 L  
-16.748 U
-7.835 83 <0.001
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Figure 3: (a) Health talk. (b) Adherence counseling. (c) ART pharmacy. 
(d) Group leader disturbing drugs
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traveled a minimum of 25.12 km to-and-fro the clinic monthly 
spending	and	wasting	hours	on	 the	way	 in	 tight	 traffic	with	
potential risks. The routes taken by most of the patients, as 
shown in Table	 1,	 experience	 heavy	 traffic	 on	 daily	 basis.	
The mean cost of this journey per clinic day was 996.4 naira, 
excluding other indirect/hidden costs. This money and time were 
saved over most of this 2 years period. The response from the 
patients, Table 2a, and caregivers, Table 2b, to the questions 1, 2 
and 3 respectively, “do you think this intervention have helped 
to reduce transport cost for patients to‑and‑fro the clinic?”, 
“do you think this intervention model has helped patients gain 
valuable time?” and ‘’do you think this intervention model 
may have improved patient’s income since they had more time 
for their private businesses and concerns?’ was impressively 
affirmative.	Their	purchasing	power	also	improved	as	they	used	
saved money to cater for some other needs. The patients were 
also	happier,	as	all	patients	responded	in	affirmation	to	questions	
1and 4 “has the intervention helped save more time for them 
and reduce their cost of transportation to and fro clinic” and 
“do you think this model may have helped to improve patients’ 
wellbeing ?, with mutual peer support. Some of the patients 
did not have means of direct income; they worried on how to 
reach the hospital, and depended on their relatives, who now 
spend less on their transport to and fro the clinic. ART supply, 
compliance and proper motivation were guaranteed. These 
favored good outcomes,[24-26] and of course, better nutrition 
among others. All the health care workers and patients agreed 
that the model is helping to improve the quality of care.
Nutrition improvement
Nutritional status is obviously a major determinant of the 
outcome	not	only	in	pediatrics	but	also	in	adult	HIV	treatment	
and care.[27]	HIV	infection	increases	basal	energy	requirements	
several folds, and more in cases with OIs, and malabsorption.[28] 
Furthermore,	anorexia,	which	is	common	among	HIV	patients,	
is a cause of weight loss.[29]
These potential changes in nutritional status may affect 
PCV,[30] (nutritional anemia), alongside patients’ weight 
and weight changes,[7,31] which may thus be used as indirect 
measures of nutritional status.[7] There were significant 
increases in (P	<	0.001)	in	PCV,	weight	and	BMI,	Table 3, 
with a possible increase in metabolic risk as depicted by the 
high	mean	BMI	26.79	±	4.282	kb/m2.
This positive nutritional impact may be explained by the fact 
that these patients who now had a better understanding of the 
disease and were better motivated by the group membership 
had better nutrition, good drug compliance, and negligible 
rates of secondary infections. During the 2 years period, 
none of the patients, as followed, had a major illness, hospital 
admission,	or	died.	The	BMI	trend,	which	shows	increasing	
metabolic risk, calls for lifestyle education, and this should 
be done early.
Cardio‑metabolic impacts
Cardiovascular disease (CVD) risk factors, such as hypertension, 
are	common	in	the	HIV	population	as	well	and	may	predispose	
them to related complications.[32] Our study used hypertension, 
height,	weight,	and	BMI	as	cardio‑metabolic	risk	assessment	
tools.[7,31]	The	CAG	model	 showed	 some	 cardio‑metabolic	
impacts	on	the	patients	with	a	significant	reduction	in	blood	
pressure,	inferring	reduced	CVD	risk	profile[33] and improved 
anthropometric measures, as shown in Table 3. Aside from 
the blood pressure reduction, the patients gained weight 
with	 a	 significant	 increase	 in	BMI.	As	 previously	 noted,	
studies	now	show	that	PLHIV	experience	a	disproportionate	
amount of noncommunicable disease burden, partly due to 
the high prevalence of traditional risk factors among them[32] 
and increased life-expectancy. No wonder atherosclerotic 
cardiovascular‑disease	is	a	leading	cause	of	non‑HIV‑related	
death	among	ART‑experienced	PLHIV.[34-36]
Thus	 increase	 in	mean	BMI	 above	 the	 accepted	 healthy	
limits[37] in this study is a wake-up call for early lifestyle 
intervention	 for	ART‑treated	PLHIV,	 especially	 those	with	
good drug compliance.
Overall impact on quality of care and the facility
This	is	obviously	a	major	impact	following	the	significant	
reduction	in	the	group	mean	viral	load,	a	significant	increase	
in CD4 counts, improved RIC among others. None of the 
patients dropped out of care, had treatment failure, died, 
or needed emergency review by the physician during the 
review period. Adherence to drugs was impressive as it 
improved even more. The mean adherence at entry and after 
2 years was 87.55% and 100% respectively, (P < 0.001). 
Interestingly, these impacts on individuals rubbed off on the 
groups. From the questionnaire, most of the patients believed 
that the intervention had increased their quality of life. 
Table 2 showed that group members received and exchanged 
valuable mutual psychosocial support, and particularly, 
advised each other on adherence issues. This may have 
resulted in better disease knowledge, drug compliance, 
better nutrition, all impacting on and yielding an impressive 
adherence.	 Such	 group‑membership	 as	 depicted	 in	CAG,	
and seen as a family, has been shown to enable patients to 
realize	that	they	are	not	the	only	ones	living	with	HIV	and	
needing treatment, thus creating strong bond and network 
between the members.[38-43]
On	the	hospital	facility	and	system;	overall,	the	CAG	model	
was perceived as contributing to improved health outcomes. 
Both	the	patients	and	caregivers	reported	better	retention	on	
ART	with	no	patients	lost	to	follow‑up	and/or	died.	The	CAG	
model has also impacted on the knowledge, attitude and 
practice of caregivers and clients. Earlier, Rasschaert et al.[14] 
reported	that,	in	the	CAG	model,	group	members	assume	some	
other informal health-care responsibilities in both the clinic 
and community. Such responsibilities include; education and 
motivation	of	peers	as	well	as	tracing	of	other	HIV‑patients	
who were lost to follow-up.[14] Other roles as seen in our 
setting,	were;	identification	of	ill	people	and	even	sensitization	
of	people	in	the	community	to	go	for	HIV	testing.	Patients	in	
our facility carry out these roles passively, and such action 
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may have contributed to the increased uptake of health-care 
services,	including	HIV	testing	and	care	in	our	facility.
Many	HIV‑positive	 patients	 are	 employed	 to	work	 in	 our	
hospital, acting as a veritable support to the system. This is 
because, as coordinator, I have observed that, the more patients 
were involved in the health-care service system, the better the 
trust	and	communication.	Recall	that	the	CAG	desk‑officer	is	
an expert client. There is better communication within patients’ 
groups and between patients and care-givers. Some of our 
patients proffer advice on some hospital health-related policies. 
Workload at the clinic is reducing and will be felt more when 
the	CAG	model	is	scaled	up,	freeing	up	more	time	to	attend	
to complicated cases.
The main limitation of the study was the seemingly small 
sample size. Despite the small size, (which was the number 
we	had	for	 the	CAG	pilot),	 it	has	obviously	revealed	some	
usefulness of this model, thus justifying the on-going scale 
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